# The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.

> **NCT02914652** · PHASE4 · COMPLETED · sponsor: **University of Aarhus** · enrollment: 96 (actual)

## Conditions studied

- Ventricular Septal Defect

## Interventions

- **DRUG:** Salbutamol
- **DRUG:** Norflouran (Placebo Evohaler(R) )

## Key facts

- **NCT ID:** NCT02914652
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-15
- **Primary completion:** 2017-07-01
- **Final completion:** 2018-01-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914652, "The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02914652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*